Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

  • Hydrogen
  • greenhydrogen
  • Biotechnology

Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.

Read

Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

  • Biotechnology
  • Pharma

In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?

Read

Commented by André Will-Laudien on June 10th, 2024 | 06:45 CEST

Nasdaq short bets remain dangerous! TUI, Saturn Oil + Gas, Plug Power, and Evotec in the crosshairs

  • Mining
  • Oil
  • renewableenergies
  • Travel
  • Biotechnology

Last week, Nvidia shares gave the bears a scare. Despite massive price gains in recent months, the shares of the specialist for high-performance chips gained another 20%, adding USD 600 billion to its valuation. Now, behind Microsoft, Nvidia is the second most valuable company in the world, surpassing even Apple. Of course, this did not happen without reason because, as of today, the share is trading at 1:10, which means a tenfold increase in the number of shares in the portfolio for shareholders. This does not change the market value per se, as the share price is also reduced by 90% at the opening. The aim is to make the share more accessible and allow retail investors to get involved. Stock splits of this kind are common on the NASDAQ and have often brought investors additional price gains in the following months. Where are the opportunities for investors?

Read

Commented by André Will-Laudien on June 6th, 2024 | 07:00 CEST

Rally start for biotech! Evotec, Bayer, Defence Therapeutics, CureVac and BioNTech in pole position

  • Biotechnology
  • Pharma

Sell in May and go Away! Far from it, as the stock markets continue to rise steadily in June. After a disappointing start to the year, the biotech sector is now also showing signs of recovery. Bayer and Evotec seem to have found their footing with improved outlooks. BioNTech, CureVac and Defence Therapeutics are providing promising data on various cancer vaccines. Whoever opens the door here can save millions of lives. And investors stand to make a fortune if one of the vaccines hits the mark. We analyze the opportunities and risks.

Read

Commented by Stefan Feulner on June 4th, 2024 | 07:00 CEST

Canopy Growth, Vidac Pharma, BioNTech - Opportunities after the correction

  • Biotechnology
  • Pharma

After record highs for the DAX, Dow Jones, and the precious metal gold, the stock market has been burdened by a broad correction in recent days, which could spread further in the coming weeks. However, the setback offers many investors the opportunity to pick up their favorites once again at discounted levels. In addition to the highly volatile cannabis stocks, there are enormous opportunities in the biotech sector, where takeovers are on the rise.

Read

Commented by André Will-Laudien on May 30th, 2024 | 07:00 CEST

Already up 180% in 2024 - Who offers more? BioNTech, Bayer, Cardiol Therapeutics, or Evotec?

  • Biotechnology
  • Pharma

For investors in the biotech sector, 2024 has been a very rocky year. Everyone is waiting for the big breakthrough, which has yet to appear. In a sector where there is no longer a pandemic and cancer research is still stuck, selection has become very important. Complicating matters is the investor-unfriendly capital market interest rate, with hopes resting on support from central banks quarter by quarter. This makes it all the more important to identify and follow the most innovative business models. BioNTech does not currently have a blockbuster but still has a good EUR 17 billion in its coffers. Pharmaceutical giant Bayer has seen its share price drop to a fifth of its 2019 value, and Evotec also resembles a disaster. Cardiol Therapeutics has performed well so far - what is next for them?

Read

Commented by Fabian Lorenz on May 29th, 2024 | 07:00 CEST

Biotech stocks with a comeback! BioNTech, Evotec, Vidac Pharma

  • Biotechnology
  • Pharma

Avian flu has caused vaccine stocks such as BioNTech, Moderna and CureVac to soar in the past week; however, more is needed to ensure a sustainable comeback. BioNTech plans to achieve this with cancer drugs. In an interview with "Handelsblatt", BioNTech's CEO expressed his optimism about significantly reducing the mortality rate. The Mainz-based company plans to launch its first drugs on the market as early as 2026. Vidac Pharma is pursuing a revolutionary approach in the fight against cancer. The London-based biotech company has published promising study data and is being traded as a takeover candidate. And what about Evotec? The problem child of the current year has extended a partnership but continues to search for a trigger to drive its stock up.

Read

Commented by Juliane Zielonka on May 24th, 2024 | 07:00 CEST

NVIDIA, Vidac Pharma, Bayer - Opportunities for innovation and growth

  • Pharma
  • Biotechnology
  • Growth
  • AI

The next industrial revolution has begun – companies and countries are working with firms like NVIDIA to transform traditional data centres worth billions of euros into accelerated computing hubs and build a new type of data centre: AI factories to produce artificial intelligence. The areas of application are vast, including data processing, generative AI, pharmaceutical research, weather simulations, robotics and many more. Vidac Pharma, for example, is an exciting candidate in the field of drug research. Their innovative approach in oncology can reverse the function of cancer cells. If successful, Bayer would have less to worry about. The Leverkusen-based company is fighting the wave of US lawsuits in connection with RoundUp®. The glyphosate-based herbicide is suspected of causing cancer. Bayer is now pursuing a new strategy in the face of the six-figure lawsuits. Where do investors find the best innovations and greatest growth opportunities?

Read

Commented by Juliane Zielonka on May 23rd, 2024 | 08:45 CEST

Defence Therapeutics, Super Micro Computer, Evotec: Fresh patents, revenue explosion, and cyberattacks - These companies overcome all hurdles

  • Biotechnology
  • Pharma
  • AI

Medicine and research go hand in hand. The Canadian biotech company Defence Therapeutics is expanding its patent protection for its platform technology in order to further advance the development of drugs, vaccines, and active ingredients. Data collection and analysis require intelligent solutions such as those from Super Micro Computer. With an incredible 200% increase in revenue, the US company from Silicon Valley is surfing the digital wave of success. Will they continue to rise? Meanwhile, Evotec is grappling with the darker side of digitalization. Due to a cyberattack, the life sciences company is withdrawing from an otherwise lucrative segment. We provide the details.

Read

Commented by Stefan Feulner on May 22nd, 2024 | 07:00 CEST

BioNTech, Cardiol Therapeutics, Morphosys - On the verge of a breakout

  • Biotechnology
  • Pharma

Compared to the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition to takeovers, which have increased dramatically in 2024, many companies have important study results in the pipeline that could kick-start a rally.

Read